Media Releases

2018 News & Press Release

IDEXX to Introduce Applied BioCode's Innovative Multiplex Technology Across Global Reference Laboratory Network

January 8, 2018 –

WESTBROOK, Maine--(BUSINESS WIRE) -- IDEXX Laboratories, Inc. (NASDAQ: IDXX) and Applied BioCode (6598:Taipei) today announced that they have entered into an exclusive global agreement to bring Applied BioCode's digital multiplex platform to IDEXX Reference Laboratory customers. IDEXX anticipates the technology will be commercially available starting in 2019. Applied BioCode is a California-headquartered diagnostics company which designs, develops, manufactures, and markets systems for highly multiplexed assays.

"IDEXX's market-leading innovation is at the core of our strategy," said Jonathan Ayers, Chairman and Chief Executive Officer of IDEXX Laboratories. "Implementation of Applied BioCode's technology supports our vision for margin expansion, and will allow us to offer customers expanded test menu breadth and menu customization for each patient sample submitted to IDEXX Reference Labs in the future. This is consistent with our commitment to provide the most comprehensive, cost-effective and timely diagnostic picture for our customers and their patients. This proprietary technology platform will also likely have applications in our other animal health diagnostic markets."

Paired with IDEXX's proprietary assays and reagents, Applied BioCode's technology enables the development of an ultra-high sensitivity immunoassay platform. Immunoassay is the detection technology used on platforms such as SNAP for applications as diverse as vector-borne disease and parasitology, and for both sick and preventive care uses.

"Applied BioCode is thrilled to introduce our technology to veterinary medicine with IDEXX, enabling veterinarians to benefit from our advanced multiplexing capabilities," said Winston Ho, President of Applied BioCode. "We look forward to working with the IDEXX team to implement our platform at its reference laboratories."

For more information about IDEXX Reference Laboratories, visit

About IDEXX Laboratories

IDEXX Laboratories, Inc. is a member of the S&P 500® Index and is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. IDEXX products enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency and build more economically successful practices. IDEXX is also a worldwide leader in providing diagnostic tests and information for livestock and poultry and tests for the quality and safety of water and milk. Headquartered in Maine, IDEXX Laboratories employs more than 7,000 people and offers products to customers in over 175 countries. For more information about IDEXX, visit:

About Applied BioCode Applied BioCode is a publicly traded diagnostic company that develops, manufactures, and markets Barcoded Magnetic Beads (BMBs) and detection systems to facilitate development of highly multiplexed nucleic acids or protein detection assays. The BMB technology offers up to 4,096 unique digital barcodes for multiplex analysis with unmatched decoding accuracy. Our easy-to-use BioCode systems employ steady state detection without requiring flow cytometers that are prone to channel blockage or sample cross contamination. The system is well suited for clinical diagnostic applications such as detection of infectious pathogens, drug resistance markers, cancer markers and mutation analysis, as well as specific applications for the life science research and agricultural testing markets. For more information, please visit the company's website at

Note Regarding Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as "expects," "may," "anticipates," "intends," "would," "will," "plans," "believes," "estimates," "should," and similar words and expressions. These forward-looking statements are based on management's current expectations and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. IDEXX assumes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Readers are advised to review IDEXX's filings with the United States Securities and Exchange Commission (which are available from the SEC's EDGAR database at and via IDEXX's website at


Applied BioCode Submits 510(k) Application to FDA for BioCode MDx-3000 with Gastrointestinal Pathogen Panel

January 3, 2018 –

SANTA FE SPRINGS, Calif.--(BUSINESS WIRE) -- Applied BioCode announced today that it has submitted the BioCode MDx-3000 with 18-Plex Gastrointestinal Pathogen Panel (GPP) to the U.S. Food and Drug Administration (FDA) for 510(k) clearance.

The BioCode MDx-3000 system was designed for high volume molecular testing in large hospitals and reference laboratories. The system automates the PCR amplification, hybridization/target capture, and detection steps of molecular diagnostic testing. It provides laboratories with the ability to run highly multiplexed panels which improves lab efficiency, reduces labor and reagent cost, minimizes sample contamination, and may result in better patient outcomes.

The BioCode MDx-3000 system offers the high volume laboratory an alternative to high cost molecular test systems. The user-friendly system also offers target masking capabilities within panels to address variation in test ordering patterns and potential changes in panel reimbursement. Bi-directional data integration to laboratory information systems simplifies laboratory processes and reduces transcription errors.

The comprehensive BioCode GPP tests for 18 of the most common bacteria, viruses, and parasites that cause infectious diarrhea. The submission of the BioCode GPP comes after the successful completion of a clinical study that included more than 1,550 prospective samples. The study was conducted at several hospital-based clinical laboratories located in different geographical areas in the United States. Applied BioCode anticipates commercial release of the BioCode MDx-3000 with GPP in the early spring of 2018, pending FDA clearance.

Dr. Winston Ho, Ph.D., Applied BioCode's President, said: "Feedback from our U.S. clinical trial sites has been extremely positive and reinforces the need for a more automated high throughput multiplex molecular test system. The clinical trial sites were very pleased with the ease-of-use of the BioCode system and their ability to quickly train their staff on the system." He followed on to say, "The Gastrointestinal Pathogen Panel will be the first of many syndromic multiplex panels to be commercialized on the BioCode MDx-3000."


2017 News & Press Release

Applied Biocode to Submit Gastrointestinal Pathogen Panel to FDA in Bid to Displace Luminex

April 20, 2017 –

NEW YORK -- (GenomeWeb, Justin Petrone) -- Applied Biocode intends to have a panel for identifying 18 different gastrointestinal pathogens on the clinical market by the end of the year.

CEO Winston Ho said that the Santa Fe Springs, California-based molecular diagnostics company will soon commence clinical trials for the assay, called the Gastrointestinal Pathogen Panel, which runs on its barcoded magnetic bead-based multiplex BioCode MDx 3000 system, at five sites in the US.

If all goes well, the company will submit the clinical trial data to the US Food and Drug Administration for 510(k) clearance by the end of June. Should the agency clear the test and system, it will become Applied Biocode's first in vitro diagnostic product on the clinical market. It will also allow the firm to directly challenge Luminex, which offers its own FDA-cleared xTAG Gastrointestinal Pathogen Panel for 14 microorganisms on several instruments.

Luminex has been offering xTAG GPP to high-volume laboratories for clinical use since 2013 and the firm has considered the assay to be a growth driver. However, according to Ho, as well as to Bob Wessel, a marketing and strategic planning consultant who works for Applied Biocode, the availability of their GPP and BioCode MDx 3000 system could temper Luminex's dominant market position.

"This is a very rapidly growing market and customers with whom we have talked about the system really want it badly," Wessel said of Applied Biocode's offering. "We are planning to displace Luminex," he noted. "Luminex is a non-automated system, some of their customers have not been happy with that, and they are looking for another solution."

Representatives for Luminex declined to comment on Applied Biocode's statements.

Ho, who is also Applied Biocode's CTO, founded the firm in 2008 to commercialize its barcoded magnetic bead technology, where DNA targets are coupled to barcoded beads, providing a high-contrast transmitted signal, no fluorescence background, and nearly 100 percent decoding accuracy, according to the company. Applied Biocode's BMB technology provides up to 4,096 unique digital barcodes for multiplex analysis, he noted, and the technology is protected by several US patents.

The new BioCode MDx 3000 system is based on a 96-well microplate format, which should spur its adoption in clinical labs, Ho said. The system automates the PCR amplification, hybridization, and detection steps of the assay, and it can process up to 94 patient samples in less than five hours.

"It's a high-throughput, automated multiplex system, and we are targeting the high-volume labs with it," said Ho of the company's offering.

Applied Biocode has long eyed the infectious disease testing market as a primary opportunity for the technology, and its GPP has been in development for years. The assay simultaneously detects and differentiates between 18 diarrhea-causing pathogens, including bacteria like Campylobacter and E. coli O157, viruses such as Rotavirus A, and parasites like Giardia lamblia.

Ho said that the company also has a respiratory virus panel in its pipeline, and would seek FDA clearance for that test, too, once it sees its BioCode MDx 3000 system cleared for clinical use. Wessel commented that Applied Biocode also offers a version of the system that will enable users to run their own custom assays, therefore easing its path to adoption for laboratory-developed tests. For this, the company will also have Luminex as a main competitor, which already offers an FDA-cleared xTAG Respiratory Virus Panel and enables customers to develop their own tests.

Applied Biocode recently concluded beta site trials for its GPP assay at the University of California, Los Angeles, and at Poplar Healthcare, a Memphis, Tennessee-based laboratory services company. Ho said that one of the beta users will take part in the clinical trial as well, although he declined to say which one or name any of the other sites.

Anami Patel, vice president of genomics operations and development at Poplar Healthcare, oversaw the beta trial at that site and said that it is possible that Applied Biocode could win over customers who are looking for greater automation for gastrointestinal pathogen testing.

"When Luminex introduced multiplex testing for that indication, it brought a very good molecular tool into the market as a first mover," Patel said. "Our physicians were very excited about ordering that test when it became available and I had never seen such excitement for such a test."

Though the xTAG GPP takes about six or seven hours to complete, he said, it was "still better than culture," the conventional method that many labs still employ, and "brought a lot of efficiency" to his laboratory.

While he noted that Applied Biocode's GPP has a few more targets than Luminex's offering, he said that its greater degree of automation is also a positive for Applied Biocode's offering as there is "less room for error." To date, Poplar has run about 400 specimens on the system, and Patel said that Applied Biocode's automation, as well as its software, which he described as easy to use, are both important for lab efficiency.

Pricing for the system remains unknown, although Ho said it will be competitive. Patel said that he is "very curious" about how much Applied Biocode's offering might cost, adding that an automated system like the BioCode MDx 3000 would certainly fit into Poplar's workflow, where about 90 specimens are analyzed every day. Because of that volume load, other, less automated offerings, such as BioMérieux's BioFire Diagnostics FilmArray Gastrointestinal Panel, which gained FDA clearance in 2016 and allows users to test for the presence of 22 different pathogens in one sample at a time, are not directly competitive for Poplar's lab. "BioFire won't fit into our workflow," he said.

It is unclear if Luminex is planning to update the GPP to counter any challenge from Applied Biocode. In recent months, the company has progressed with bringing in vitro diagnostics to market, albeit on its newer, real-time PCR-based ARIES system. In January, for instance, it gained FDA clearance for its Aries Group B Streptococcus (GBS) assay for antepartum detection of GBS colonization in pregnant women. Last year, the company also acquired Nanosphere for $58 million, and integrating the molecular diagnostics company has also been a focus for Luminex.

Like Patel, Sanjib Bhattacharyya, laboratory director of the City of Milwaukee Health Department, who has used Luminex's xTAG GPP, described the assay as "the first of its kind" on the market but acknowledged that there would be many more and that molecular testing had become "very popular" in labs that conduct infectious disease testing versus conventional culture.

However, he said that some public health reference labs are concerned that these new platforms miss the opportunity for culture-based antimicrobial susceptibility testing, which he described as "critical" for assessing microbial drug resistance as well as for future drug development. He also said that the availability of such high-throughput multiplex systems, like the ones offered by Applied Biocode, would only increase the need for skilled clinical interpretation.

"Since these panels will bring in lots of information, understanding the cause of diseases and symptoms, [and] infection versus colonization for some of those pathogens will be important for optimal therapy and antibiotic use, for those [in] need," said Bhattacharyya.

He added that while resistance detection is currently limited on such panels, it may become available as the field moves from phenotypic to genotypic susceptibility testing. He suggested that test developers increase their cooperation with clinical and public health reference laboratories, to spur such advances.

"Infection control practitioners will be valuable for defining algorithms and judicious use of these enteric panels," Bhattacharyya said.


Applied BioCode Completes Beta Sites for Molecular Diagnostic System

March 29, 2017 07:07 AM Eastern Daylight Time –

SANTA FE SPRINGS, Calif.--(BUSINESS WIRE)--Today, Applied BioCode announced that they have completed their beta site trials for the BioCode MDx 3000 and their 18-Plex Gastrointestinal Pathogen Panel. The beta site trials were held at both the University of California, Los Angeles, and at the Poplar Healthcare Laboratory in Memphis, TN, and were completed during January and February this year. Applied BioCode have begun shipping systems to their clinical evaluation sites in March. "Completing the beta site trials is an exciting milestone for Applied BioCode," stated Winston Ho, President of Applied BioCode. "We have tested our new investigational molecular diagnostics system in clinical laboratories and have gotten excellent feedback on the diagnostic utility of the BioCode MDx 3000 system."

At Poplar Healthcare, Anami Patel, Ph.D., Vice President of Genomics Operations and Development, was in charge of the Beta Site Trial. He stated: "The BioCode MDx 3000 performed very well in our laboratory. Once we were trained on the BioCode MDx 3000 system we found it very easy to operate. We expect the BioCode MDx 3000 system to provide a workflow advantage for our laboratory and will be an ideal solution for high volume, highly multiplex molecular diagnostic testing."

At the UCLA Health System, Romney Humphries, Ph.D., Section Chief of Clinical Microbiology and Assistant Professor, stated, "We completed the beta testing on the BioCode MDx 3000 system and it went well." Winston Ho also said that he expects that the clinical evaluations from five sites will be concluded by June with submission to the FDA in the subsequent months. FDA 510k clearance is possible in the 4th quarter of 2017.


Applied BioCode Listed on Taiwan Emerging Market Stock Exchange

February 09, 2017 06:07 AM Eastern Standard Time –

SANTA FE SPRINGS, Calif.--(BUSINESS WIRE)--Applied BioCode is pleased to announce that they have been accepted for listing on the Taiwan Emerging Market Stock Exchange (ticker symbol 6598).

As a registered Cayman Island corporation with facilities in the United States and Taiwan, Applied BioCode designs, develops, and commercializes innovative high value automated products for the Molecular Diagnostics medical industry. Their products and services will revolutionize the industry providing hospitals and reference laboratories with the ability to perform rapid, high volume, low cost molecular diagnostic testing for multiple pathogens. The Applied BioCode automated system* with multiplexing testing capability will allow earlier intervention of therapy by physicians, provide improved outcomes for patients, and globally lower overall healthcare costs.

Dr. Winston Ho, President of Applied BioCode, stated that he is very pleased that they have qualified for acceptance onto the Taipei Stock Exchange.


2016 News & Press Release

Applied BioCode Inks Partnership and Supply Agreement with Diatherix for Multiplex MDx Reference Laboratory Testing

June 16, 2016 4:07 AM Pacific Daylight Time –

SANTA FE SPRINGS, Calif.--(BUSINESS WIRE)--Applied BioCode announced that it has signed a Partnership and Supply Agreement with Diatherix Laboratories, LLC, a Eurofins company. Diatherix Laboratories will utilize Applied BioCode's Barcoded Magnetic Beads and BioCode detection systems in conjunction with their proprietary TEM-PCR™ technology to develop highly sensitive multiplex molecular diagnostic infectious disease panels for their laboratory customers.

"We are very pleased to partner with Diatherix Laboratories in this important area of the market," said Winston Ho, President of Applied BioCode. "Our Barcoded Magnetic Beads combined with the Diatherix TEM-PCR™ technology will provide an elegant solution for multiplexing of molecular diagnostic infectious disease tests. We embrace their ability to quickly identify co-infections and link diagnostics testing to the right therapeutic to significantly improve patient outcomes and reduce overall healthcare costs."

"We are pleased to partner with Applied BioCode for their Barcoded Magnetic Bead technology," said Dennis Grimaud, CEO of Diatherix Laboratories. "Their Barcoded Magnetic Bead technology will allow us to reduce the development timeframe to bring new multiplex test panels to market and enhance the sensitivity of our molecular diagnostic panels. We look forward to a long and successful partnership with Applied BioCode."


Applied BioCode Awarded Digital Barcode Patent for Identifying Multiplexed Biomarkers or Pathogens

February 09, 2016 11:48 AM Pacific Standard Time –

SANTA FE SPRINGS, Calif.--(BUSINESS WIRE)--The first patent for a digital barcode was issued to inventors Joseph Woodland and Bernard Silver in 1949. Decades later, in 1974, the first scanner for reading digital barcodes was installed at a Marsh's supermarket in Troy, Ohio. Digital Barcodes soon became the industry standard and the most widely used method for identifying information on millions of products. Applied BioCode today announced that the United Stated Patent and Trademark Office has granted US Patent #9,255,922 (February 9, 2016), describing the material and method of a digital barcode, which is 1,000 times smaller than the conventional barcodes, for simultaneously identifying thousands of bacteria, viruses, pathogens, or biomarkers. This patented Barcoded Magnetic Bead allows the 4,096 available barcodes to be easily scanned and accurately identified with no ambiguity.

Applied BioCode develops biopolymer-base micrometer scale barcoded magnetic beads, which not only have great physical properties (density, rigidity, temperature, pressure, shelf-life stability) and chemical properties (pH stability, surface chemistry, bio-functionalities), but also have excellent biological compatibility (nucleic acids, proteins, buffers, and long term stability) for biological applications. "The new patent expands our four earlier granted patents including the optical scanner that is responsible for decoding the digital barcode and identifying each analyte target in the sample," said Winston Ho, Ph.D., President of Applied BioCode. "These patents solidify our intellectual property portfolio by further protecting our encoded polymer bead technology and providing our products with long term market value."

Applied BioCode is currently developing an 18-plex Gastrointestinal Pathogen Panel for the most common pathogens including viruses, bacteria and parasites that cause infectious diarrhea. The 18-Plex GI Pathogen Panel will be run on the BioCode MDx 3000 Molecular Diagnostic System. This system combines the amplification, hybridization, and detection steps with the capability to run up to 188 samples in an 8-hour shift, and up to three different multiplexed panels simultaneously. The multiplexed panels are run in a low cost, high throughput 96 well microplate format. The automation of these steps into a single system will decrease reagent costs, reduce hands on time, and minimize the potential risk of sample contamination. Submission to FDA is expected later this year.


2015 News & Press Release

Applied BioCode to Present Poster at AMP on 18-Plex GI Pathogen Panel with a High Throughput System

October 20, 2015 11:34 AM Pacific Daylight Time –

SANTA FE SPRINGS, Calif.--(BUSINESS WIRE)--Applied BioCode announced today that its abstract for a poster on "18-Plex Gastrointestinal Pathogen Detection with a User Friendly, High Throughput System" has been accepted for presentation at the Association for Molecular Pathology meeting, November 5-7 in Austin, TX.

The poster will cover the development progress of Applied BioCode's new high throughput, multiplex automated MDx system. The new BioCode platform utilizes Applied BioCode's proprietary Barcoded Magnetic Beads (BMB) and fully automates the process of amplification, target capture and detection for molecular diagnostic assays.

The poster will also provide the latest analytical and performance data for the 18-plex Gastrointestinal Pathogen Panel that is currently in development. The BioCode 18-plex GI Pathogen Panel includes targets for the bacteria (Campylobacter, Clostridium difficile toxin A&B, Salmonella, Shigella, E. coli O157, Enterotoxigenic E. coli, Enteropathogenic E. coli, Shiga toxin producing E. coli, Enteroaggregative E. coli, Vibrio spp., Vibro parahaemolyticus, Vibro Vulnificus, Vibro Cholerae, Yersinia Enterocolitica), viruses (norovirus group I/II, adenovirus 40/41, rotavirus A), and parasites (Giardia, Cryptosporidium, Entamoeba histolytica).

Preliminary data generated for the Gastrointestinal Pathogen Panel with the automated system will be presented by Applied BioCode's scientific personnel.


May 5, 2015 - Applied BioCode Licenses Patents to Molecular Devices.

April 22, 2015 - Applied BioCode to Present Poster at CVS on Multiplex Gastrointestinal Pathogen Detection with a User Friendly, High Throughput Molecular Diagnostic System.

March 31, 2015 - Applied BioCode Expands PerkinElmer Deal for Infectious Disease MDx in Asia.

2014 News & Press Release

April 15, 2014 - Applied BioCode to Present Poster at CVS on Multiplex Gastrointestinal Pathogen Detection with a User Friendly, High Throughput System.

January 07, 2014 - Applied BioCode Licenses its Barcoded Magnetic Bead Technology to Genetic Analysis AS for Multiplex Molecular Diagnostic Testing of Microbial Imbalances in the GI Tract.

2013 News & Press Release

August 22, 2013 - Applied BioCode passed a QSIT (quality system inspection technique) audit conducted by the U.S. Food and Drug Administration (FDA) on August 21, 2013 with No Action Indicated (NAI) for a Class II medical device manufacturer of Barcoded Magnetic Beads (BMB) and BMB Analyzers.

April 25, 2013 - Applied BioCode Launches the BioCode-2000 System for 128-Plex Assays.

April 18, 2013 - Applied BioCode Appoints Michael Aye, Ph.D. as its Vice President of Molecular Products for its Molecular Diagnostic Program.

2012 News & Press Release

August 07, 2012 - Applied BioCode Awarded Barcoded Magnetic Beads Analyzer Patent for Multiplex MDx Assays.

April 04, 2012 - Applied BioCode Granted Additional Patent for Barcoded Magnetic Beads Used for Multiplex MDx Assays.

March 28, 2012 - Applied BioCode Licenses Barcoded Magnetic Beads Technology to Douglas Scientific for High Throughput AgBio Testing.

January 10, 2012 - Hologic to Use Applied BioCode's Barcoded Magnetic Beads for Ag-Bio Tests.

2011 News & Press Release

September 19, 2011 - Applied BioCode's Quality System is Consistent with the U.S. FDA's QSR Approach.

April 19, 2011 - EraGen to Use Applied BioCode's Technology in Molecular Tests.

January 25, 2011 - Applied BioCode Granted 2 Patents for its Barcoded magnetic Beads Used in Highly Multiplexed MDx Testing.

2010 News & Press Release

June 17, 2010 - Multiplexed Assays Go Digital at the Biodetection Technologies 2010 Conference.

May 27, 2010 - Applied BioCode has Been CE Certified for its Barcoded Magnetic Beads Multiplex Testing System.

April 29, 2010 - Applied BioCode Oakridge Poster-Highly Scalable Barcoded Magnetic Beads Digital Multiplexing System for Molecular Diagnostics.